Search for: All records

The advent of ultrabroadband Internet connectivity brings a 2-3 orders of magnitude jump in the capacity of access networks (a.k.a. the “last mile”). Beyond mere capacity increase, this leap represents a qualitative shift in the overall Internet environment. Therefore, we argue that only by seizing the opportunity to re-think the way we structure network applications and services can we realize the full potential ultrabroadband provides. Specifically, with ultrabroadband residential networks, we have the opportunity to re-center our digital lives around our residence, similar to how our physical lives generally center around our homes. To this end, we introduce a new appliance in home networks–a “home point of presence”–that provides a variety of services to the users in the house regardless of where they are physically located and connected to the network. We illustrate the utility of this appliance by discussing a range of new services that both bring new functionality to the users and improve performance of existing applications. 

Systemic administration of immune checkpoint blockade (ICB) monoclonal antibodies (mAbs) can unleash antitumor functions of T cells but is associated with variable response rates and off-target toxicities. We hypothesized that antitumor efficacy of ICB is limited by the minimal accumulation of mAb within tissues where antitumor immunity is elicited and regulated, which include the tumor microenvironment (TME) and secondary lymphoid tissues. In contrast to systemic administration, intratumoral and intradermal routes of administration resulted in higher mAb accumulation within both the TME and its draining lymph nodes (LNs) or LNs alone, respectively. The use of either locoregional administration route resulted in pronounced T cell responses from the ICB therapy, which developed in the secondary lymphoid tissues and TME of treated mice. Targeted delivery of mAb to tumor-draining lymph nodes (TdLNs) alone was associated with enhanced antitumor immunity and improved therapeutic effects compared to conventional systemic ICB therapy, and these effects were sustained at reduced mAb doses and comparable to those achieved by intratumoral administration. These data suggest that locoregional routes of administration of ICB mAb can augment ICB therapy by improving immunomodulation within TdLNs.